N/A
18 Years
36 Years
18 Years
36 Years
Open (Enrolling)
Female
Polycystic Ovary Syndrome
Female
Polycystic Ovary Syndrome
Trial Information
Inclusion Criteria:
- age between 18 to 36
- oligo/anovulation and(or) polycystic ovary
- FG score over 8 or hyperandrogenimia
- no desire of children within one year
Exclusion Criteria:
- PCOS with regular cycles
- the exclusion of other hyperandrogenic conditions
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Outcome Measure:
Ovarian androgen biosynthesis
Outcome Description:
Ovarian androgen biosynthesis as measured by HCG-stimulated production of 17- hydroxyprogesterone (17OHP)，T，A2，DHEAS。
Outcome Time Frame:
Up to 1 year
Safety Issue:
No
Authority:
China: Ministry of Science and Technology
Study ID:
Tanshinone-HLJUCM
NCT ID:
NCT01452477
Start Date:
October 2011
Completion Date:
July 2014
Related Keywords:
- Polycystic Ovary Syndrome
- Polycystic Ovary Syndrome
- Cryptotanshinone
- Polycystic Ovary Syndrome
Name | Location |
|---|
